Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia

ABSTRACT The consensus views of an expert roundtable meeting are presented as updated management guidelines for using alemtuzumab in chronic lymphocytic leukemia. Since the publication of

previous management guidelines in 2004, clinical experience with alemtuzumab has grown significantly, especially regarding its efficacy and safety, management of cytomegalovirus (CMV)

reactivation, identification of patient subgroups likely to benefit from alemtuzumab therapy and subcutaneous administration of alemtuzumab. The updated recommendations include (1)

alemtuzumab monotherapy can be safely used as first-line therapy; (2) suitable patient subgroups for alemtuzumab therapy include elderly patients, patients with 17p deletion, patients with

refractory autoimmune cytopenias and patients with profound pancytopenia at baseline due to heavily infiltrated bone marrow; (3) alemtuzumab treatment should be continued for 12 weeks (36

doses) whenever possible, and bone marrow examination may be considered at week 12 to evaluate response; (4) monitoring CMV reactivation by weekly PCR is mandated during therapy; when CMV

reactivation becomes symptomatic or viremia increases, alemtuzumab therapy should be interrupted and anti-CMV therapy started; (5) subcutaneous administration is safe, easy to perform and

appears equally effective compared with intravenous infusion and (6) our strong recommendation is that alemtuzumab combination therapy and consolidation therapy shall not be used outside

carefully controlled clinical studies. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through

your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant

access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions *

Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS UPDATE ON THE MANAGEMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA Article Open access 21 February

2024 CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT ALGORITHM 2022 Article Open access 29 November 2022 THALIDOMIDE-BASED REGIMEN SHOWS PROMISING EFFICACY IN LARGE GRANULAR LYMPHOCYTIC LEUKEMIA: A

MULTICENTER PHASE II STUDY Article Open access 12 March 2025 REFERENCES * Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T _et al_. Cancer statistics, 2008. _CA Cancer J Clin_ 2008; 58:

71–96. Article  Google Scholar  * Watson L, Wyld P, Catovsky D . Disease burden of chronic lymphocytic leukaemia within the European Union. _Eur J Haematol_ 2008; 81: 253–258. Article 

Google Scholar  * Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L _et al_. Genomic aberrations and survival in chronic lymphocytic leukemia. _N Engl J Med_ 2000; 343:

1910–1916. Article  CAS  Google Scholar  * Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF _et al_. Assessment of fludarabine plus cyclophosphamide for patients with chronic

lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. _Lancet_ 2007; 370: 230–239. Article  CAS  Google Scholar  * Thornton PD, Gruszka-Westwood AM, Hamoudi RA,

Atkinson S, Kaczmarek P, Morilla RM _et al_. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. _Hematol J_ 2004; 5: 47–54. Article  CAS  Google Scholar  * Eichhorst

BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C _et al_. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic

lymphocytic leukemia. _Blood_ 2006; 107: 885–891. Article  CAS  Google Scholar  * Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM _et al_. Phase III trial of fludarabine

plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. _J Clin Oncol_ 2007; 25: 793–798. Article  CAS

  Google Scholar  * Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F _et al_. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and

rituximab as initial therapy for chronic lymphocytic leukemia. _J Clin Oncol_ 2005; 23: 4079–4088. Article  CAS  Google Scholar  * Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G,

Thomas D _et al_. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. _J Clin Oncol_ 2005; 23: 4070–4078. Article

  CAS  Google Scholar  * Hallek M, Fingerle-Rowson G, Fink A, Busch R, Mayer J, Hensel M _et al_. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR)

versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia

(CLL) (Abstract 325). _Blood_ 2008; 112: 125. Google Scholar  * Robak T, Moiseev SI, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J _et al_. Rituximab, fludarabine, and

cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the International

Randomized Phase III REACH Trial (abstract). _Blood_ 2008; 112: lba–lb1. Google Scholar  * Byrd JC, Stilgenbauer S, Flinn IW . Chronic lymphocytic leukemia. _Hematology (Am Soc Hematol Educ

Program)_ 2004, 163–183. * Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A . Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and

leukemias with monoclonal antibodies. _Hematol J_ 2001; 2: 300–306. Article  CAS  Google Scholar  * Riechmann L, Clark M, Waldmann H, Winter G . Reshaping human antibodies for therapy.

_Nature_ 1988; 332: 323–327. Article  CAS  Google Scholar  * Xia MQ, Hale G, Waldmann H . Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. _Mol Immunol_

1993; 30: 1089–1096. Article  CAS  Google Scholar  * Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S _et al_. Alemtuzumab induces caspase-independent cell death in human

chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. _Leukemia_ 2006; 20: 272–279. Article  CAS  Google Scholar  * Smolewski P, Szmigielska-Kaplon A, Cebula B,

Jamroziak K, Rogalinska M, Kilianska Z _et al_. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia

cells. _Leuk Lymphoma_ 2005; 46: 87–100. Article  CAS  Google Scholar  * Stanglmaier M, Reis S, Hallek M . Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic

pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. _Ann Hematol_ 2004; 83: 634–645. Article  CAS  Google Scholar  * Zent CS, Chen JB, Kurten RC, Kaushal GP, Lacy HM,

Schichman SA . Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. _Leuk Res_ 2004; 28: 495–507. Article  CAS  Google Scholar  * Zent CS, Secreto

CR, Laplant BR, Bone ND, Call TG, Shanafelt TD _et al_. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic

leukemia (CLL) treated with alemtuzumab and rituximab. _Leuk Res_ 2008; 32: 1849–1856. Article  CAS  Google Scholar  * Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J _et al_.

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. _J Clin Oncol_ 2007; 25: 5616–5623. Article  CAS  Google Scholar  * Demko S, Summers J, Keegan

P, Pazdur R . FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. _Oncologist_ 2008; 13: 167–174. Article  CAS  Google Scholar  *

Keating M, Coutre S, Rai K, Osterborg A, Faderl S, Kennedy B _et al_. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. _Clin Lymphoma_ 2004; 4: 220–227.

Article  CAS  Google Scholar  * Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V _et al_. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab

(Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). _Blood_ 2002; 100: 768–773. Article  CAS  Google Scholar  * Karlsson C, Norin S, Kimby E,

Sander B, Porwit MA, Nilsson B _et al_. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk

of Richter transformation. _Leukemia_ 2006; 20: 2204–2207. Article  CAS  Google Scholar  * Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE _et al_. Single-agent

rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.

_J Clin Oncol_ 2003; 21: 1746–1751. Article  CAS  Google Scholar  * Campath (alemtuzumab) prescribing information. http://www.campath.com/.March 2009. * O'Brien SM, Keating MJ, Mocarski

ES . Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. _Clin Lymphoma Myeloma_ 2006; 7: 125–130.

Article  CAS  Google Scholar  * Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D _et al_. Phase II multicenter study of human CD52 antibody in previously treated chronic

lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. _J Clin Oncol_ 1997; 15: 1567–1574. Article  CAS  Google Scholar  * Rawstron AC, Kennedy

B, Moreton P, Dickinson AJ, Cullen MJ, Richards SJ _et al_. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. _Blood_ 2004; 103: 2027–2031.

Article  CAS  Google Scholar  * Sayala HA, Moreton P, Kennedy B, Lucas G, Leach M, Rassam SMB _et al_. Eradication of minimal residual disease with alemtuzumab in chronic lymphocytic

leukemia is associated with prolonged survival and is an appropriate therapeutic endpoint for relapsed CLL (abstract 3114). _Blood_ 2007; 110: 916a. Google Scholar  * Keating MJ, Flinn I,

Jain V, Binet JL, Hillmen P, Byrd J _et al_. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. _Blood_ 2002; 99:

3554–3561. Article  CAS  Google Scholar  * Cortelezzi A, Pasquini MC, Sarina B, Bertani G, Grifoni F, Colombi M _et al_. A pilot study of low-dose subcutaneous alemtuzumab therapy for

patients with hemotherapy-refractory chronic lymphocytic leukemia. _Haematologica_ 2005; 90: 410–412. CAS  PubMed  Google Scholar  * Stilgenbauer S, Zenz T, Winkler D, Buhler A, Groner S,

Busch R _et al_. Subcutaneous alemtuzumab (Campath) in fludarabine-refractory CLL: final results of the CLL2H trial of the GCLLSG and comprehensive analysis of prognostic markers (abstract

329). _Blood_ 2008; 112: 127. Google Scholar  * Dyer MJS, Buckby E, Fermahan P, Walewska R, Kennedy B . Increasing the dose intensity of alemtuzumab (CAMPATH-1H) in chronic lymphocytic

leukemia (CLL): the CAM1515 study (abstract 2959). _Blood_ 2005; 106: 830a. Google Scholar  * Karlsson C, Lundin J, Kimby E, Kennedy B, Moreton P, Hillmen P _et al_. Phase II study of

subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. _Br J Haematol_ 2009; 144: 78–85. Article  CAS  Google Scholar  *

Hwang W, Dearden C, Loh SM, Linn YC, Tien SL, Teoh G _et al_. Outpatient-based therapy with oral fludarabine and alemtuzumab for Asian patients with relapsed/refractory chronic lymphocytic

leukemia (CLL) (abstract 4992). _Blood_ 2006; 108: 336b. Google Scholar  * Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning ML _et al_. Self-administered, subcutaneous

alemtuzumab to eliminate residual disease in patients with CLL (abstract 2839). _Blood_ 2006; 108: 804a. Article  Google Scholar  * Elter T, Borchmann P, Schulz H, Reiser M, Trelle S,

Schnell R _et al_. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II

trial. _J Clin Oncol_ 2005; 23: 7024–7031. Article  CAS  Google Scholar  * Montillo M, Miqueleiz S, Tedeschi A, Ricci F, Vismara E, Ciapanna D _et al_. Combined fludarabine,

cyclophosphamide, and alemtuzumab (FCC), an active regimen for treated patients with chronic lymphocytic leukemia (abstract 3133). _Blood_ 2007; 110: 922a. Google Scholar  * Wierda WG,

O'Brien S, Ferrajoli A, Faderl S, Koller C, Estrov Z _et al_. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk

patients with CLL (abstract 628). _Blood_ 2007; 110: 628a. Google Scholar  * Wierda WG, O'Brien SM, Faderl S, Ferrajoli A, Koller C, Estrov Z _et al_. CFAR, an active frontline regimen

for high-risk patients with CLL, including those with del 17p. (abstract 2095). _Blood_ 2008; 112: 729. Google Scholar  * Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM,

Giles FJ _et al_. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. _Blood_ 2003; 101: 3413–3415. Article  CAS  Google Scholar  *

Frankfurt O, Hamilton E, Acharya S, Duffey S, Raji A, Rosen ST . A phase II trial of alemtuzumab and rituximab in patients with previously untreated CLL (abstract 2056). _Blood_ 2007; 110:

612a–613a. Google Scholar  * Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA _et al_. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and

rituximab. _Cancer_ 2008; 113: 2110–2118. Article  CAS  Google Scholar  * Pettitt AR, Matutes E, Oscier D . Alemtuzumab in combination with high-dose methylprednisolone is a logical,

feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. _Leukemia_ 2006; 20: 1441–1445. Article  CAS  Google Scholar  * O'Brien SM,

Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG _et al_. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. _Cancer_

2003; 98: 2657–2663. Article  CAS  Google Scholar  * Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Rassenti LZ _et al_. Plasma alemtuzumab levels at end of treatment correlate with

response and response duration in patients with CLL receiving treatment for residual disease. (abstract 2109). _Blood_ 2008; 112: 734. Google Scholar  * Delmer A, Leprêtre S, Cazin B,

Feugier P, Tournilhac O, Leporrier M _et al_. Consolidation therapy with subcutaneous alemtuzumab following induction treatment with oral FC (fludarabine and cyclophosphamide) in previously

untreated patients aged 65–70 years with advanced stage chronic lymphocytic leukemia: a phase II trial of the FCGCLL/MW (abstract 2831). _Blood_ 2006; 108: 801a. Google Scholar  * Montillo

M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L _et al_. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with

chronic lymphocytic leukemia. _J Clin Oncol_ 2006; 24: 2337–2342. Article  CAS  Google Scholar  * Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G _et al_.

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—experience on safety and efficacy within a randomized multicenter phase III trial of the

German CLL Study Group (GCLLSG). _Leukemia_ 2004; 18: 1093–1101. Article  CAS  Google Scholar  * Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M _et al_.

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial

of the German CLL Study Group (GCLLSG). _Br J Haematol_ 2009; 144: 95–98. Article  CAS  Google Scholar  * Lin TS, Donohue KA, Lucas MS, Byrd JC, Bengston EM, Peterson BL _et al_.

Consolidation therapy with subcutaneous alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response after fludarabine and rituximab

induction therapy: interim safety analysis of the CALGB Study 10101 (abstract 755). _Blood_ 2007; 110: 232a–233a. Google Scholar  * Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden

JD, Saez RA _et al_. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic

lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. _Cancer_ 2008; 112: 1288–1295. Article  CAS  Google Scholar  * Eichhorst BF, Busch R, Stauch M, Bergmann M, Ritgen M,

Kranzhofer N _et al_. No significant clinical benefit of first line therapy with fludarabine (F) in comparison to chlorambucil (Clb) in elderly patients (pts) with advanced chronic

lymphocytic leukemia (CLL): results of a phase III study of the German CLL Study Group (GCLLSG) (abstract 629). _Blood_ 2007; 110: 194a. Google Scholar  * Stilgenbauer S, Dohner H .

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. _N Engl J Med_ 2002; 347: 452–453. Article  Google Scholar  *

Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J _et al_. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. _Blood_ 2004;

103: 3278–3281. Article  CAS  Google Scholar  * Osuji NC, Del GI, Matutes E, Wotherspoon AC, Dearden C, Catovsky D . The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia

in relation to cytogenetic abnormalities of p53. _Haematologica_ 2005; 90: 1435–1436. CAS  PubMed  Google Scholar  * Pitini V, Arrigo C, Naro C, Buemi B, Marabello G, Santarpia M _et al_.

Subcutaneous low-dose alemtuzumab as first line therapy for elderly CLL patients with deletion of 17p (abstract 7048). _J Clin Oncol_ 2008; 26 (Suppl): 384s. Google Scholar  * Barcellini W,

Capalbo S, Agostinelli RM, Mauro FR, Ambrosetti A, Calori R _et al_. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia.

_Haematologica_ 2006; 91: 1689–1692. PubMed  Google Scholar  * Karlsson C, Hansson L, Celsing F, Lundin J . Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic

lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). _Leukemia_ 2007; 21: 511–514. Article  CAS  Google Scholar  * Laurenti L, Tarnani M, Efremov DG, Chiusolo P, De

PL, Sica S _et al_. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. _Leukemia_ 2007; 21: 1819–1821.

Article  CAS  Google Scholar  * Osterborg A, Karlsson C, Lundin J, Kimby E, Mellstedt H . Strategies in the management of alemtuzumab-related side effects. _Semin Oncol_ 2006; 33: S29–S35.

Article  Google Scholar  * Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A _et al_. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after

alemtuzumab therapy is associated with prolonged survival. _J Clin Oncol_ 2005; 23: 2971–2979. Article  CAS  Google Scholar  * O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand

J _et al_. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. _Blood_ 2008; 111: 1816–1819. Article  CAS  Google Scholar  * Fiegl M,

Falkner F, Falkner A, Zojer N, Fridrik M, Hopfinger G _et al_. Retreatment with alemtuzumab after a first, successful alemtuzumab treatment in B-CLL (abstract 4714). _Blood_ 2007; 110: 252b.

Google Scholar  * National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma, v.2.200.

http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. 2009. Download references ACKNOWLEDGEMENTS We thank Wei Jiang (SciStrategy Communications) for his medical writing

assistance, which was supported by Bayer Healthcare Pharmaceuticals. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Hematology, Karolinska University Hospital, Stockholm, Sweden

A Österborg * Department of Oncology, Karolinska Institute, Stockholm, Sweden A Österborg * Division of Hematology, Department of Cellular Biotechnologies and Hematology, ‘Sapienza’

University, Rome, Italy R Foà * Department of Hematology, Hospital General de Agudos, Buenos Aires, Argentina R F Bezares * Department of Haemato-Oncology, C Dearden * The Royal Marsden

Hospital and Institute of Cancer Research, London, UK C Dearden * MRC Toxicology Unit, University of Leicester, Leicester, UK M J S Dyer * Department of Hematology, Rigshospitalet,

Copenhagen, Denmark C Geisler * Division of Hematology and Oncology, The Ohio State University, Columbus, OH, USA T S Lin * Department of Hematology, Niguarda Ca' Granda Hospital,

Milan, Italy M Montillo * Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands M H J van Oers * Clinic I of Internal Medicine, University of Cologne, Cologne,

Germany C-M Wendtner * Division of Hematology-Oncology, Long Island Jewish Medical Center, New Hyde Park, NY, USA K R Rai Authors * A Österborg View author publications You can also search

for this author inPubMed Google Scholar * R Foà View author publications You can also search for this author inPubMed Google Scholar * R F Bezares View author publications You can also

search for this author inPubMed Google Scholar * C Dearden View author publications You can also search for this author inPubMed Google Scholar * M J S Dyer View author publications You can

also search for this author inPubMed Google Scholar * C Geisler View author publications You can also search for this author inPubMed Google Scholar * T S Lin View author publications You

can also search for this author inPubMed Google Scholar * M Montillo View author publications You can also search for this author inPubMed Google Scholar * M H J van Oers View author

publications You can also search for this author inPubMed Google Scholar * C-M Wendtner View author publications You can also search for this author inPubMed Google Scholar * K R Rai View

author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to A Österborg. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS

ARTICLE CITE THIS ARTICLE Österborg, A., Foà, R., Bezares, R. _et al._ Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. _Leukemia_ 23, 1980–1988 (2009).

https://doi.org/10.1038/leu.2009.146 Download citation * Received: 08 April 2009 * Revised: 25 May 2009 * Accepted: 04 June 2009 * Published: 23 July 2009 * Issue Date: November 2009 * DOI:

https://doi.org/10.1038/leu.2009.146 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * alemtuzumab * dosing schedule * elderly * infections *

safety